A61K38/1767

Food compositions containing added honey proteins
11576414 · 2023-02-14 ·

Food composition supplemented with one or more honey proteins provide additional protein without detracting from flavor or mouthfeel and may also possess cytostimulatory properties. The honey proteins may be royal jelly major proteins (RJMP) such as those from the western honeybee Apis mellifera. The honey proteins can be created by expression of recombinant DNA in a yeast or bacterium. The honey protein is selected based on physical properties of the protein and of the food composition to reduce negative mouthfeel and flavor characteristics that may be caused by added protein. Multiple different proteins may be added in a specified ratio to create a desired texture or cytostimulatory property.

METHODS OF TREATING VASCULAR LESIONS AND MALFORMATIONS
20230037660 · 2023-02-09 ·

Compositions and formulations comprising peptide conjugate compounds are provided, including native and modified variants of chlorotoxin peptide conjugated to detectable agents or active agents. Methods of detecting and treating vascular lesions, vascular malformations, and vascular abnormalities including cerebral cavernous malformation (CCM) with peptide conjugate compounds are also provided, including methods of imaging and resecting vascular lesions tissues and cells.

METHOD FOR TREATING ANGELMAN SYNDROME AND RELATED DISORDERS
20230042176 · 2023-02-09 ·

The present invention relates to methods of treating or ameliorating seizures relating to disruptions in Ubiquitin Protein Ligase E3A (UBE3A) gene. More particularly, the invention relates to the use of BK channel antagonists for the prophylaxis or treatment of seizures in a subject with Angelman syndrome or related autism spectrum disorder (ASD). In some embodiments, BK channel antagonist is Paxilline, iberiotoxin (IBTX) or GAL-021.

Inhibitors of LTβR-NFκB signaling pathways for treating inflammation and cancer

The present invention provides compositions and methods for selective inhibition of the classical or non-classical LTβR-NFκB signaling pathway. In some embodiments, the compositions and methods of the present invention are useful for treating or preventing tissue graft rejection, inflammation, contact hypersensitivity, and cancer by decreasing cell motility.

Methods and compositions with purified <i>Bombyx mori </i>cocoon silk peptide fiber and refined <i>Buglossoides arvensis </i>seed oil providing anti-inflammatory effects and neuroprotection for disease states

The present invention is directed to compositions comprising purified Bombyx mori cocoon silk peptide fiber, refined Buglossoides arvensis seed oil, and optionally Blueberry extract, and related methods for decreasing inflammation and providing neuroprotection. The compositions provide synergistic effects and may be used to treat relevant diseases and disorders.

PHARMACEUTICAL COMPOSITION COMPRISING SMALL OCTOPUS-DERIVED PEPTIDE FOR TREATMENT OF INFLAMMATORY DISEASE
20230024652 · 2023-01-26 ·

The present invention relates to a pharmaceutical composition for treating inflammatory disease containing a peptide derived from Octopus minor. The novel antibacterial peptide or fragment thereof according to the present invention may efficiently inhibit pro-inflammatory cytokines and chemokines responsible for inflammatory responses in LPS-activated macrophages, and thus may be effectively used to prevent or treat inflammatory disease.

Injectable silk fibroin foams and uses thereof

The inventions provided herein relate to compositions, methods, delivery devices and kits for repairing or augmenting a tissue in a subject. The compositions described herein can be injectable such that they can be placed in a tissue to be treated with a minimally-invasive procedure (e.g., by injection). In some embodiments, the composition described herein comprises a compressed silk fibroin matrix, which can expand upon injection into the tissue and retain its original expanded volume within the tissue for a period of time. The compositions can be used as a filler to replace a tissue void, e.g., for tissue repair and/or augmentation, or as a scaffold to support tissue regeneration and/or reconstruction. In some embodiments, the compositions described herein can be used for soft tissue repair or augmentation.

COMPOSITION MODULATING BOTULINUM NEUROTOXIN EFFECT

The present invention relates to a method for modulating the effect of a botulinum neurotoxin composition, that is accelerating the onset of action and/or extending the duration of action and/or enhancing the intensity of action of a botulinum neurotoxin composition, comprising adding at least one postsynaptic inhibitor of cholinergic neuronal transmission to the botulinum neurotoxin composition. The invention also relates to compositions comprising at least one postsynaptic inhibitor of cholinergic neuronal transmission and a botulinum neurotoxin, and their uses for treating aesthetic or therapeutic conditions.

COMPOSITION MODULATING BOTULINUM NEUROTOXIN EFFECT

The present invention relates to a method for modulating the effect of a botulinum neurotoxin composition, that is accelerating the onset of action and/or extending the duration of action and/or enhancing the intensity of action of a botulinum neurotoxin composition, comprising adding at least one postsynaptic inhibitor of cholinergic neuronal transmission to the botulinum neurotoxin composition. The invention also relates to compositions comprising at least one postsynaptic inhibitor of cholinergic neuronal transmission and a botulinum neurotoxin, and their uses for treating aesthetic or therapeutic conditions.

ENTERIC-COATED GRANULAR COMPOSITION COMPRISING INGREDIENTS DERIVED FROM BEE VENOM AND LACTIC ACID BACTERIA

Proposed is an enteric-coated granular composition containing an ingredient derived from bee venom and lactic acid bacteria. The enteric-coated granular composition containing a bee venom-derived ingredient and lactic acid bacteria according to the present invention has an immune enhancing effect by increasing cytotoxic T cells, helper T cells, or B cells and the weight of lymph nodes; and a recovery effect on kidney injury by decreasing expression of cytokine TNF-α, IL-1β and NGAL.